Acerus Pharmaceuticals Corp (ASP)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Acerus Pharmaceuticals Corp (ASP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012241
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Acerus Pharmaceuticals Corp (Acerus), formerly Trimel Pharmaceuticals Corporation, is a pharmaceutical company that develops, manufactures, markets and distributes innovative branded products. It focuses on men’s and women’s health. The company uses its proprietary drug delivery technology platforms, which include a bioadhesive nasal gel and the TriVair Deposition/Dispersion System, for the delivery of its products. Acerus’s product portfolio includes Estrace, which is approved in Canada for relief from menopausal symptoms; Natesto, a testosterone nasal gel, which is approved by the US FDA for the treatment of male hypogonadism and filed for approval in Canada. Acerus is headquartered in Mississauga, Ontario, Canada.

Acerus Pharmaceuticals Corp (ASP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Acerus Pharmaceuticals Corp, Medical Devices Deals, 2011 to YTD 2017 10
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million 13
Partnerships 15
Trimel Pharma Enters Into Co-Development Agreement With European Company 15
Licensing Agreements 16
Apsen Farmaceutica Enters into Licensing Agreement with Acerus Pharma 16
Eu Hwa Enters into Licensing Agreement with Acerus Pharma for NATESTO 17
medac Enters into Licensing Agreement with Acerus Pharma for NATESTO 18
Therios Healthcare Enters into Licensing Agreement with Acerus Pharma for NATESTO 19
Hyundai Pharma Enters into Licensing Agreement with Acerus Pharma 20
Aytu BioScience Enters into Licensing Agreement with Acerus Pharma 21
Acerus Pharma Enters into Licensing Agreement with Medinova 22
Equity Offering 23
Acerus Pharma Raises USD2 Million in Private Placement of Shares 23
Trimel Pharma Raises USD16.6 Million in Private Placement of Shares 24
Trimel Pharma Announces Full Exercise Of Underwriter’s Option For Public Offering Of Shares For US$45 Million 25
Trimel Pharma Announces Rights Offering Of Shares 27
Trimel Pharma Completes Public Offering Of Units For US$13 Million 28
Trimel BioPharma Completes Private Placement Of Units For US$30 Million 30
Debt Offering 31
Trimel Pharma Raises USD25 Million in Private Placement of 9.5% Convetible Note Due 2015 31
Acquisition 32
J5 Acquisition And J5 (Barbados) Complete Acquisition Of Trimel BioPharma 32
Acerus Pharmaceuticals Corp – Key Competitors 33
Acerus Pharmaceuticals Corp – Key Employees 34
Acerus Pharmaceuticals Corp – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Nov 07, 2017: Acerus Reports Third Quarter 2017 Financial Results 36
Aug 11, 2017: Acerus Reports Second Quarter 2017 Financial Results 38
Mar 08, 2017: Acerus Reports Fourth Quarter and Full Year 2016 Financial Results 40
Nov 02, 2016: Acerus Reports Third Quarter 2016 Financial Results 42
Aug 09, 2016: Acerus Reports Second Quarter 2016 Results 44
May 04, 2016: Acerus Reports First Quarter 2016 Results and Provides Business Update 46
Mar 02, 2016: Acerus Reports Fourth Quarter and Full Year 2015 Financial Results 48
Corporate Communications 50
Dec 07, 2017: Acerus Appoints Mr. Mark Lievonen to its Board of Directors 50
Oct 02, 2017: Acerus Announces Executive Leadership Change 51
May 05, 2017: Acerus Announces Appointment of Ken Yoon as Chief Financial Officer 52
Nov 01, 2016: Acerus Announces Appointment of Tricia Symmes as Chief Operating Officer 53
Jul 21, 2016: Acerus Appoints Mr. Luc Mainville to Its Board of Directors 54
Mar 24, 2016: Acerus Announces Departure of Dr. Michael Bumby 55
Legal and Regulatory 56
May 17, 2016: Acerus Provides Update on Litigation 56
Apr 08, 2016: Acerus comments on statement of claim 57
Apr 05, 2016: Litigation Against Acerus Pharmaceuticals Continues 58
Mar 09, 2016: Eugene Melnyk Initiates Legal Proceedings Against Acerus Pharmaceuticals, its Chairman, Ihor Ihnatowycz, and Others 59
Other Significant Developments 60
Dec 21, 2016: Acerus Comments on Decision Regarding Litigation 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acerus Pharmaceuticals Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Acerus Pharmaceuticals Corp, Medical Devices Deals, 2011 to YTD 2017 10
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million 13
Trimel Pharma Enters Into Co-Development Agreement With European Company 15
Apsen Farmaceutica Enters into Licensing Agreement with Acerus Pharma 16
Eu Hwa Enters into Licensing Agreement with Acerus Pharma for NATESTO 17
medac Enters into Licensing Agreement with Acerus Pharma for NATESTO 18
Therios Healthcare Enters into Licensing Agreement with Acerus Pharma for NATESTO 19
Hyundai Pharma Enters into Licensing Agreement with Acerus Pharma 20
Aytu BioScience Enters into Licensing Agreement with Acerus Pharma 21
Acerus Pharma Enters into Licensing Agreement with Medinova 22
Acerus Pharma Raises USD2 Million in Private Placement of Shares 23
Trimel Pharma Raises USD16.6 Million in Private Placement of Shares 24
Trimel Pharma Announces Full Exercise Of Underwriter's Option For Public Offering Of Shares For US$45 Million 25
Trimel Pharma Announces Rights Offering Of Shares 27
Trimel Pharma Completes Public Offering Of Units For US$13 Million 28
Trimel BioPharma Completes Private Placement Of Units For US$30 Million 30
Trimel Pharma Raises USD25 Million in Private Placement of 9.5% Convetible Note Due 2015 31
J5 Acquisition And J5 (Barbados) Complete Acquisition Of Trimel BioPharma 32
Acerus Pharmaceuticals Corp, Key Competitors 33
Acerus Pharmaceuticals Corp, Key Employees 34
Acerus Pharmaceuticals Corp, Subsidiaries 35

★海外企業調査レポート[Acerus Pharmaceuticals Corp (ASP)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Amerisafe Inc:企業の戦略・SWOT・財務分析
    Amerisafe Inc - Strategy, SWOT and Corporate Finance Report Summary Amerisafe Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Valecha Engineering Ltd
    Valecha Engineering Ltd - Strategy, SWOT and Corporate Finance Report Summary Valecha Engineering Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Gecina SA:企業のM&A・事業提携・投資動向
    Gecina SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Gecina SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Tenet Healthcare Corp (THC):製薬・医療:M&Aディール及び事業提携情報
    Summary Tenet Healthcare Corp (Tenet) is a health care services company that operates hospitals, diagnostic imaging centers, ambulatory surgery centers, and related health care facilities along with its subsidiaries and affiliates. The company serves urban and rural communities in US through general …
  • TriWest Healthcare Alliance Corp:企業の戦略的SWOT分析
    TriWest Healthcare Alliance Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • The State Export-Import Bank of Ukraine:企業の戦略・SWOT・財務情報
    The State Export-Import Bank of Ukraine - Strategy, SWOT and Corporate Finance Report Summary The State Export-Import Bank of Ukraine - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Tongaat Hulett Ltd (TON):企業の財務・戦略的SWOT分析
    Tongaat Hulett Ltd (TON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • BioMarker Strategies LLC-医療機器分野:企業M&A・提携分析
    Summary BioMarker Strategies LLC (BioMarker Strategies) is a biotechnology company that develops tissue-based cancer diagnostic systems. The company offers cancer diagnostics system for predictive tests to targeted treatments for solid tumor malignancies. It also offers pathmap functional signaling …
  • Kazanci Holding AS:電力:M&Aディール及び事業提携情報
    Summary Kazanci Holding AS (Kazanci) is an investment holding company. The company operates in the business of power generation, natural gas distribution, energy generation and electricity distribution and sales. It operates through business segments such as Aksa Energy, Aksa Electricity, Aksa Power …
  • Choppies Enterprises Ltd:企業の戦略的SWOT分析
    Choppies Enterprises Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • NorthStar Realty Finance Corp:企業のM&A・事業提携・投資動向
    NorthStar Realty Finance Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NorthStar Realty Finance Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Cheniere Energy Inc (LNG):企業の財務・戦略的SWOT分析
    Cheniere Energy Inc (LNG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Spark Therapeutics Inc (ONCE):企業の財務・戦略的SWOT分析
    Summary Spark Therapeutics Inc (Spark) is a clinical-stage gene therapy company which provides gene therapies for inherited retinal diseases (IRDs), neurodegenerative diseases, as well as liver diseases. Its pipeline products include SPK-RPE65, SPK-CHM, rhonova, LHON, SPK-FIX, SPK-FVIII and SPK-TPP1 …
  • Harbin Electric Co Ltd (1133):企業の財務・戦略的SWOT分析
    Harbin Electric Co Ltd (1133) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • ThyssenKrupp AG:企業の戦略・SWOT・財務分析
    ThyssenKrupp AG - Strategy, SWOT and Corporate Finance Report Summary ThyssenKrupp AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Insmed Inc (INSM):製薬・医療:M&Aディール及び事業提携情報
    Summary Insmed Inc (Insmed) is a biopharmaceutical company that focuses on rare diseases. Its lead product candidate, Arikayce (liposomal amikacin for inhalation), is indicated for the treatment of nontuberculous mycobacteria (NTM) lung disease in adult patients. Its other clinical pipeline are bein …
  • Biogen, Inc.:戦略・SWOT・企業財務分析
    Biogen, Inc. - Strategy, SWOT and Corporate Finance Report Summary Biogen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Northern Sun Mining Corp:企業の戦略・SWOT・財務分析
    Northern Sun Mining Corp - Strategy, SWOT and Corporate Finance Report Summary Northern Sun Mining Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Vietnam Export Import Commercial Joint Stock Bank
    Vietnam Export Import Commercial Joint Stock Bank - Strategy, SWOT and Corporate Finance Report Summary Vietnam Export Import Commercial Joint Stock Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structur …
  • St. Jude Children’s Research Hospital Inc-製薬・医療分野:企業M&A・提携分析
    Summary St. Jude Children’s Research Hospital Inc (St. Jude) is a healthcare service provider that offers research and clinical care services for children with catastrophic diseases. The hospital provides treatment programs such as brain tumors, leukemia, infectious diseases, immunodeficiency diseas …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆